Enveric Biosciences, Inc. (NASDAQ:ENVB – Get Free Report) was up 3.6% during mid-day trading on Tuesday. The company traded as high as $1.4450 and last traded at $1.44. Approximately 31,300 shares traded hands during trading, a decline of 53% from the average session volume of 66,353 shares. The stock had previously closed at $1.39.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on ENVB shares. Wall Street Zen upgraded shares of Enveric Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enveric Biosciences in a research note on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has a consensus rating of “Sell”.
View Our Latest Stock Analysis on Enveric Biosciences
Enveric Biosciences Stock Down 3.3%
The firm has a market capitalization of $6.54 million, a P/E ratio of -0.12 and a beta of 1.18. The company has a fifty day simple moving average of $1.45 and a 200 day simple moving average of $1.83.
Enveric Biosciences (NASDAQ:ENVB – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.76) earnings per share for the quarter.
About Enveric Biosciences
Enveric Biosciences, Inc is a biotechnology company focused on discovering and developing novel therapeutics for cancer and central nervous system disorders. The company’s research programs draw on cannabinoid- and psychedelic-inspired compounds intended to address unmet medical needs while potentially avoiding some of the limitations associated with naturally occurring compounds.
Enveric has developed a pipeline of investigational small-molecule drug candidates, including programs aimed at neuropsychiatric conditions such as depression and cancer-related complications.
Further Reading
- Five stocks we like better than Enveric Biosciences
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
-corinth-refineries-sa-logo-1200x675.png){kind=logo}
